Friday, July 31, 2026

Jang Dong-hyuk’s U.S. Meetings: Uncovering the Secrets Behind Korea-U.S. Alliance Discussions

Jang Dong-hyuk of the People Power Party discusses U.S. relations and intelligence leaks in a meeting with Deputy Ambassador Heller.

Unlock the Future: A Comprehensive Guide to Meta’s AI Glasses and Their Amazing Capabilities

Meta launched AI glasses in Korea, enabling hands-free interaction with an AI assistant for real-time information and translation.

North Korea Launches New 5,000 Ton Destroyer Choe Hyon: What This Means for Regional Naval Power

North Korea celebrates the launch of a new destroyer at Nampo Shipyard, emphasizing self-reliance and production targets across industries.

Jung Eun Kim

Author's Latest

Cancer Gone for 3 Years? This New Drug Is Making It Happen

AbbVie's Epkinly shows 96% long-term complete remission in R/R large B-cell lymphoma patients, highlighting its effectiveness as a therapy.

J&J Aims to Treat Cancer Before It Starts Showing Symptoms

Johnson & Johnson leads in multiple myeloma treatment, pioneering early intervention for high-risk patients with a new subcutaneous formulation.

Opdivo Wins EU Approval in Big Step for Early Lung Cancer Treatment

Opdivo gains EU approval for perioperative therapy in NSCLC, enhancing competition with Keytruda and marking a treatment paradigm shift.

Ozempic Maker Swaps CEO, Bets $2.2B on New Obesity Drug Fight

Novo Nordisk's leadership change aims to reclaim its obesity treatment market share amid competition from Eli Lilly's Mounjaro.

New Study: Mounjaro Helps Users Drop Over 50 Pounds

Eli Lilly's Mounjaro leads U.S. obesity drug market, outperforming semaglutide in weight loss efficacy and safety.

Novo Nordisk and Lilly Block Generics, Tighten Grip on $125B GLP-1 Market

Novo Nordisk and Eli Lilly secure court victories against generics, maintaining dominance in the GLP-1 treatment market amid rising demand.

Novo Nordisk Pushes for First Oral Obesity Drug Approval

Novo Nordisk seeks FDA approval for oral Wegovy, potentially the first oral obesity treatment, amid competition with Eli Lilly.

Eli Lilly’s Oral GLP-1 Shows 7.9% Weight Loss in Type 2 Diabetes Trial

Eli Lilly's orforglipron shows promise in Phase 3 trials for diabetes and obesity, offering an oral alternative to injectables.

President Yoon Announces Historic Oil Discovery in South Korea

After President Yoon announced the "potential for a massive amount of oil and natural gas reserves off Pohang," oil stocks have risen.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.